15th Jun 2015 11:28
SAINT HELIER (Alliance News) - ArmaGen Inc. announced the company has achieved a clinical milestone and is entitled to a milestone payment from Shire PLC in conjunction with dosing patients in Phase 1 clinical trial of AGT-182, an investigational treatment of Hunter syndrome.
ArmaGen Inc is a privately held biotechnology company focused on developing revolutionary therapies to treat severe neurological disorders.
ArmaGen entered into a worldwide licensing and collaboration agreement with Shire PLC in 2014 to develop AGT-182 for the treatment of both the central nervous system and somatic (body-related) manifestations of Hunter syndrome. ArmaGen is responsible for conducting the Phase 1 study of AGT-182. ArmaGen will receive R&D funding, development and sales milestones, and future royalties from Shire.
Copyright RTT News/dpa-AFX
Related Shares:
Shire